The FDA announced an update to the indication and usage section of the Metformin Hydrochloride Tablets USP label, effective July 13, 2026. This revision explicitly states that the tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus.
Background
Metformin Hydrochloride is a well-established medication used in the management of type 2 diabetes. This label update from the FDA formalizes and reiterates its role. The updated indication specifies that Metformin Hydrochloride Tablets USP are to be used as an adjunct to diet and exercise to improve glycemic control in individuals diagnosed with type 2 diabetes mellitus, encompassing both adult and pediatric populations.
What this means
This label revision for Metformin Hydrochloride Tablets USP clarifies the scope of its approved use. For clinicians, researchers, and patient advocates, the updated indication provides precise language regarding the drug's application: it serves as a foundational therapy alongside lifestyle interventions to manage blood glucose levels in patients with type 2 diabetes, including children. This update reinforces the established utility of metformin hydrochloride in a broad patient demographic.
Source
This information was sourced from the FDA, detailing a major label revision for Metformin Hydrochloride Tablets USP, effective July 13, 2026. The complete updated label details are available on dailymed.nlm.nih.gov, identified by setid fb890205-5d43-41eb-97b2-fb0dcdd3a950.